NASDAQ : KRYS

Krystal Biotech, Inc.

$335.19 USD

$7.69 (2.35%)

Volume
520.34K
Average Volume
408.46K
Market Capitalization
$9.88B
P/E Ratio
43.25
Dividend Yield
0.00%
Price Target
$327.00
Year High
$382.54
Year Low
$130.50
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$9.46
Company Overview

NASDAQ

Krish S. Krishnan

Biotechnology

Healthcare

KRYS

295

US

USD

https://www.krystalbio.com

412 586 5830

501147102

0001711279

Liquidity Metrics

0.01

9.46

9.06

4.65

0.00

Sales & Valuation

$389.13M

23.68

7.69

41.63

8.11

Profitability

$6.84

$204.83M

53.92%

49.68%

19.25%

16.11%

P/E Metrics

43.25

0.54

0.54

Analyst Price Target & Rating

$327.00

$474.00

$300.00

Buy

4/5

17 Analysts

2.50%

Financial Health Scores

49.80

5/9

$911.94M

$1.4B

$120.24M

$194.03M

Key Metrics (TTM)

$9.39B

22.50

46.79

9.46

19.25%

13.85%

2.29%

2.40%

$86.81

579 days

Company Executives
Name Title
Kathryn A. Romano Executive Vice President & Chief Accounting Officer
John Thomas EVP, General Counsel & Corporate Secretary
John Karakkal Vice President of North American Sales & Marketing
Josh Suskin Senior Director & Head of US Human Resources
Krish S. Krishnan Founder, Chairman, President & Chief Executive Officer
Laurent Goux Executive VP & Head of International
Christine Wilson Senior VP & Head of US Commercial
Stephane Paquette Senior Vice President of Corporate Development
David Chien Senior Vice President of Clinical Development
Suma Krishnan Founder, President of R&D and Director
Poll Results

No votes yet today — be the first to share your view!

About Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier d ... iscovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Assetmark Inc. Makes New Investment in Krystal Biotech, Inc. $KRYS

2026-07-26 04:09:20

Assetmark Inc. bought a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,157 shares of the company's stock, valued at approximately $816,000. A number of other institutional

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

2026-07-24 17:00:00

Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area. Exelixis has carved out a niche in the cancer-drug market, which much larger companies typically dominate.

Krystal Biotech, Inc. $KRYS Shares Purchased by Fifth Third Bancorp

2026-07-24 04:03:48

Fifth Third Bancorp boosted its stake in Krystal Biotech, Inc. (NASDAQ: KRYS) by 3,958.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,925 shares of the company's stock after acquiring an additional 5,779 shares during the quarter. Fifth

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

2026-07-23 17:00:00

PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

2026-07-20 17:42:00

NEW YORK, July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600

3 Soaring Stocks That May Have More Upside Ahead

2026-07-07 19:15:00

The sky is the limit for these companies.

Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?

2026-06-29 09:51:05

Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs

2026-06-26 14:40:22

Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.

Frequently Asked Questions

What is the current Krystal Biotech, Inc. (KRYS) stock price?

Krystal Biotech, Inc.(NASDAQ:KRYS) stock price is $335.19 in the last trading session. During the trading session, KRYS stock reached the peak price of $382.535 while $130.5 was the lowest point it dropped to. The percentage change in KRYS stock occurred in the recent session was 2.35% while the dollar amount for the price change in KRYS stock was $7.69.

KRYS's industry and sector of operation?

The NASDAQ listed KRYS is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of KRYS?

Kathryn A. Romano | Executive Vice President & Chief Accounting Officer
John Thomas | EVP, General Counsel & Corporate Secretary
John Karakkal | Vice President of North American Sales & Marketing
Josh Suskin | Senior Director & Head of US Human Resources
Krish S. Krishnan | Founder, Chairman, President & Chief Executive Officer

How many employees does KRYS have?

Number of KRYS employees currently stands at 295. KRYS operates from 2100 Wharton Street, Pittsburgh, PA 15203, US.

Link for KRYS official website?

Official Website of KRYS is: https://www.krystalbio.com

How do I contact KRYS?

KRYS could be contacted at phone #412 586 5830 and can also be accessed through its website. KRYS operates from 2100 Wharton Street, Pittsburgh, PA 15203, US.

How many shares of KRYS are traded daily?

The average number of KRYS shares traded daily for last 3 months was 408.46K.

What is the market cap of KRYS currently?

The market value of KRYS currently stands at $9.88B with its latest stock price at $335.19